Safety and Tolerability of Adjuvant Atezolizumab Following Chemotherapy in Patients With Stage II-IIIA Non-Small Cell Lung Cancer Who Had Pneumonectomy or Bilobectomy: Results From the IMpower010 Trial
This presentation reports safety and tolerability according to type of surgery patients underwent in IMpower010 (NCT02486718), a randomized, open-label, phase III study of adjuvant atezolizumab compared with best supportive care in patients with completely resected stage IB-IIIA NSCLC who received adjuvant cisplatin-based chemotherapy. The reported data include adverse events (AEs), time to adjuvant treatment, and atezolizumab treatment withdrawal and duration in patients who had pneumonectomy or bilobectomy vs those who had lobectomy or sleeve lobectomy.